It’s not COVID-19 that’s killing Americans. It is Remdesivir poisoning causing acute kidney failure, pulmonary edema, flooding their lungs with water and they’re drowning them to death, which is why they’re requiring, supposedly, to vent these people. And that’s what’s killing these people, is Remdesivir poisoning, not COVID-19. Now, how do I know this? Amazingly, 2.2 million people in 2020 died worldwide from COVID-19. America and all of its population, including immigrants, illegals — it doesn’t matter — citizens. The total is 4.5% of the entire world’s population is in America, yet, in the entire world where COVID went wild across the globe, there were 550,000 dead Americans. That’s almost a quarter of entire world’s deaths. Do you want to know why people in America had the highest death rates from COVID-19, supposedly? It’s because in May 2020, in the same memo, Anthony Fauci asked our federal government, in May 2020, to buy up the entire stock from Gilead Sciences, of all of their Remdesivir and only treat Americans with it until the end of 2020. And then he said, at the end of 2020, you can share it with other countries. We were the only country treating people in ICUs with Remdesivir. It was already proven to cause acute kidney failure in a combined 31% of all people in that cohort study. The 23% experienced serious adverse events of multiple organ failure and acute kidney failure. Another 8% had to be taken off the drug for the same things, but it was just worse, by day 5. That’s 31% total. So 550,000 people, a quarter of all the deaths of COVID-19 was achieved by using Remdesivir, a proven deadly treatment. If I asked you, where did 99% of everybody who died from COVID-19 in America, where did they die? In ICUs. What were they doing in ICUs? They were only [giving] Remdesivir. That’s the only thing they were allowed to use. You were actually firing doctors in hospitals using hydroxychloroquine, ivermectin, budesonide, whatever else they were using. So this is how they achieved their agenda.
— Dr. Bryan Ardis
The study performed before the COVID-19 pandemic cited by Dr. Ardis shows that Remdesivir is dangerous. And yet, Anthony Fauci said that Remdesivir was “safe and effective” when the EUA was issued. In October 2020, the FDA approved Remdesivir. From the time Remdesivir was given its EUA until its approval, 400,000 people died. The other two studies had been completed by then.
Dr. Ardis has been receiving letters from patients who have left the ICU against medical advice, thanks to information about Remdesivir shared by Dr. Ardis.
Given that Anthony Fauci uses the words “safe and effective” to describe Remdesivir, can he be trusted when he uses those words to describe anything else? Given that the FDA approved this obviously dangerous drug, can we trust any of their other recent drug approvals? How is “safe and effective” defined by the FDA?
Sources:
- May 4, 2020. “Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment.” US Food & Drug Administration. FDA.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment.
Food & Drug Administration. - April 16, 2020. “Emergency Use Authorization (EUA) for Remdesivir, an Unapproved Product Center for Drug Evaluation and Research (CDER) Review.” US Food & Drug Administration, April, 37.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/EUA%20Review%20Remdesivir_050120.pdf.
Food & Drug Administration, PDF.
Related:
- September 19, 2021. David Whited and Stacy Whited with Bryan Ardis. What Is More Dangerous? (COVID-19 or the COVID-19 Hospital Protocols?). Thrivetime Show: Business School without the BS. Runtime: 1:42:57.
https://rumble.com/vmp4pz-what-is-more-dangerous-covid-19-or-the-covid-19-hospital-protocols.html.
Video, Expert. - Bryan Ardis. “The Dr. Ardis Show :: A Voice for Truth in the Modern Day.” The Dr. Ardis Show.
https://www.thedrardisshow.com/.
Expert. - December 12, 2019. Sabue Mulangu, Lori E. Dodd, Richard T. Davey, Olivier Tshiani Mbaya, Michael Proschan, Daniel Mukadi, Mariano Lusakibanza Manzo, Didier Nzolo, Antoine Tshomba Oloma, Augustin Ibanda, Rosine Ali, Sinaré Coulibaly, Adam C. Levine, Rebecca Grais, Janet Diaz, H. Clifford Lane, Jean-Jacques Muyembe-Tamfum, PALM Writing Group; Billy Sivahera, Modet Camara, Richard Kojan, Robert Walker, Bonnie Dighero-Kemp, Huyen Cao, Philippe Mukumbayi, Placide Mbala-Kingebeni, Steve Ahuka, Sarah Albert, Tyler Bonnett, Ian Crozier, Michael Duvenhage, Calvin Proffitt, Marc Teitelbaum, Thomas Moench, Jamila Aboulhab, Kevin Barrett, Kelly Cahill, Katherine Cone, Risa Eckes, Lisa Hensley, Betsey Herpin, Elizabeth Higgs, Julie Ledgerwood, Jerome Pierson, Mary Smolskis, Ydrissa Sow, John Tierney, Sumathi Sivapalasingam, Wendy Holman, Nikki Gettinger, David Vallée, Jacqueline Nordwall, and PALM Consortium Study Team. “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.” The New England Journal of Medicine 381 (24): 2293–2303.
https://doi.org/10.1056/NEJMoa1910993.
Research Journal.
ZMapp and Remdesivir were eliminated from the study following an interim analysis during the trial for mortality reasons. Remdesivir was the most dangerous drug in that trial. This trial did not include a control. This trial was funded by NIAID. - June 11, 2020. Jonathan Grein, Norio Ohmagari, Daniel Shin, George Diaz, Erika Asperges, Antonella Castagna, Torsten Feldt, Gary Green, Margaret L. Green, François-Xavier Lescure, Emanuele Nicastri, Rentaro Oda, Kikuo Yo, Eugenia Quiros-Roldan, Alex Studemeister, John Redinski, Seema Ahmed, Jorge Bernett, Daniel Chelliah, Danny Chen, Shingo Chihara, Stuart H. Cohen, Jennifer Cunningham, Antonella D’Arminio Monforte, Saad Ismail, Hideaki Kato, Giuseppe Lapadula, Erwan L’Her, Toshitaka Maeno, Sumit Majumder, Marco Massari, Marta Mora-Rillo, Yoshikazu Mutoh, Duc Nguyen, Ewa Verweij, Alexander Zoufaly, Anu O. Osinusi, Adam DeZure, Yang Zhao, Lijie Zhong, Anand Chokkalingam, Emon Elboudwarej, Laura Telep, Leighann Timbs, Ilana Henne, Scott Sellers, Huyen Cao, Susanna K. Tan, Lucinda Winterbourne, Polly Desai, Robertino Mera, Anuj Gaggar, Robert P. Myers, Diana M. Brainard, Richard Childs, Timothy Flanigan. “Compassionate Use of Remdesivir for Patients with Severe Covid-19.” The New England Journal of Medicine 382 (24): 2327–36.
https://doi.org/10.1056/NEJMoa2007016.
Research Journal.
31% of patients had serious adverse events. (23% + 8%) The most common serious adverse events — multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension — were reported in patients who were receiving invasive ventilation at baseline. - September 2020. Marie Dubert, Benoit Visseaux, Valentina Isernia, Lila Bouadma, Laurène Deconinck, Juliette Patrier, Paul-Henri Wicky, Diane Le Pluart, Laura Kramer, Christophe Rioux, Quentin Le Hingrat, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Jade Ghosn, Francois-Xavier Lescure. “Case Report Study of the First Five COVID-19 Patients Treated with Remdesivir in France.” International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases 98 (September): 290–93.
https://doi.org/10.1016/j.ijid.2020.06.093.
Research Journal.
Four of the trial patients had to be removed from the trial early: two because they were heading toward liver failure, and two because they had such severe kidney failure they they required transplants. Two of the trial patients ultimately died. France decided that Remdesivir was too dangerous to use in their country. - April 2021. Alexandre O. Gérard, Audrey Laurain, Audrey Fresse, Nadège Parassol, Marine Muzzone, Fanny Rocher, Vincent L. M. Esnault, and Milou-Daniel Drici. “Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.” Clinical Pharmacology and Therapeutics 109 (4): 1021–24.
https://doi.org/10.1002/cpt.2145.
Research Journal.